ENDRA Life Sciences' mission is to bring new capabilities to ultrasound and broaden access to better healthcare.
ENDRA is developing a next generation Thermo-Acoustic Enhanced UltraSound (TAEUS™) system to enable clinicians to visualize human tissue composition, function and temperature in ways previously possible only with CT & MRI -- at a fraction of the cost, and at the point-of-care.
ENDRA's first TAEUS application will focus on the quantification of fat in the liver, for early detection and monitoring of Non-Alcoholic Fatty Liver Disease, which affects over 1 billion people globally.
|Jan 15, 2020||ENDRA Life Sciences Renews GE Healthcare Collaboration Agreement|
|Dec 19, 2019||ENDRA Life Sciences Submits Technical File for CE Mark|
|Dec 11, 2019||ENDRA Life Sciences Completes $8.1 Million Private Placement|
|Nov 13, 2019||ENDRA Life Sciences Provides Business Update and Reports Third Quarter 2019 Financial Results|
|Nov 05, 2019||ENDRA Life Sciences to Host Third Quarter 2019 Financial Results Conference Call and Webcast on Wednesday, November 13, 2019 at 4:30 p.m. ET|
|Day Range||1.79 - 1.89|
|52 Week Range||0.62 - 3.49|
|Bid/Ask||1.87 / 1.89|
|Bid/Ask Size||200 X 1,100|
|Market Cap||14.13 million|
|Shares Outstanding||7.52 million|
|Dividend/Yield||0.00 / 0.00%|
|P/E Ratio (TTM)||N/A|